The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tkachenko E.A.

Stavropol State Medical University

Elkanov R.A.

Stavropol State Medical University

Raevskaya A.I.

Stavropol State Medical University

Vyshlova I.A.

Stavropol State Medical University

Karpov S.M.

Stavropol State Medical University

Monoclonal antibodies to calcitonin gene-related peptide receptor for episodic migraine on the example of erenumab

Authors:

Tkachenko E.A., Elkanov R.A., Raevskaya A.I., Vyshlova I.A., Karpov S.M.

More about the authors

Journal: Russian Journal of Pain. 2023;21(1): 73‑77

DOI: 10.17116/pain20232101173

Read: 3348 times

Download PDF (RU)
Contact the author
Table of contents

MONOCLONAL ANTIBODIES TO CALCITONIN GENE-RELATED PEPTIDE RECEPTOR FOR EPISODIC MIGRAINE ON THE EXAMPLE OF ERENUMAB
MONOCLONAL ANTIBODIES TO CALCITONIN GENE-RELATED PEPTIDE RECEPTOR FOR EPISODIC MIGRAINE ON THE EXAMPLE OF ERENUMAB

To cite this article:

Tkachenko EA, Elkanov RA, Raevskaya AI, Vyshlova IA, Karpov SM. Monoclonal antibodies to calcitonin gene-related peptide receptor for episodic migraine on the example of erenumab. Russian Journal of Pain. 2023;21(1):73‑77. (In Russ.)
https://doi.org/10.17116/pain20232101173

Подписка 2025 Российский журнал боли (Russian Journal of Pain)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Recu­rrent pain syndromes in adolescents of different ages. Russian Journal of Pain. 2025;(2):24-31
Prophylactic treatment of migraine in real clinical practice. Russian Journal of Pain. 2025;(2):63-69
Biofeedback in complex therapy of pain syndromes. Russian Journal of Pain. 2025;(2):70-75
Oxidative stress in the pathogenesis of chro­nic headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):35-40
The rela­tionship of diet and nutrition with the frequency of migraine atta­cks. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):30-35
The role of gene­tic poly­morphisms in folate meta­bolism genes in the mani­festation of migraine in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):47-52
Meniere’s disease and vestibular migraine: differential diagnostics and treatment. Russian Bulletin of Otorhinolaryngology. 2025;(1):57-63
Biochemical features of migraine pathogenesis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):21-26
Morning headaches in patients with obstructive sleep apnea syndrome: Pathogenesis, differential diagnosis, and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):92-97
Neurological complications invo­lving the cervical spine as a cause of adve­rse outcome in patients with rheumatoid arthritis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):133-140
Abstract:

OBJECTIVE

To analyze national and foreign available literature data for the period 2012—2022 devoted to the use of monoclonal antibodies to the CGRP ligand and receptor for episodic migraine.

MATERIAL AND METHODS

We reviewed 38 articles over the past 10 years devoted to up-to-date information on episodic migraine, modern approaches to treatment and prevention.

RESULTS

Monoclonal antibodies to the CGRP ligand and receptor are characterized by similar efficacy or superior to modern pharmacological agents. This is confirmed by several randomized clinical trials devoted to migraine prevention. Incidence of adverse reactions was minimal.

CONCLUSION

Modern drugs for migraine are not always effective and sometimes cause various adverse reactions. In this regard, monoclonal antibodies to the CGRP ligand and receptor is a promising method for migraine therapy.

Keywords:

headache
migraine
CGRP
monoclonal antibodies

Authors:

Tkachenko E.A.

Stavropol State Medical University

Elkanov R.A.

Stavropol State Medical University

Raevskaya A.I.

Stavropol State Medical University

Vyshlova I.A.

Stavropol State Medical University

Karpov S.M.

Stavropol State Medical University

Received:

11.10.2022

Accepted:

15.11.2022

Close metadata

References:

  1. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative lifetime migraine incidence in women and men. Cephalalgia: an International Journal of Headache. 2008;28(11):1170-1178. https://doi.org/10.1111/j.1468-2982.2008.01666.x
  2. Puledda F, Shields K. Non-Pharmacological Approaches for Migraine. Neurotherapeutics. 2018;15(2):336-345.  https://doi.org/10.1007/s13311-018-0623-6
  3. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019;37(4):631-649.  https://doi.org/10.1016/j.ncl.2019.06.001
  4. Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25(2):23-34. 
  5. GBD 2016 Headache Collaborators. Stovner LJ, Nichols E, Steiner TJ et al. Global, regional, and national burden of migraine and tension-type headache, 1990—2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976.  https://doi.org/10.1016/S1474-4422(18)30322-3
  6. Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;15(2):304-312.  https://doi.org/10.1007/s13311-018-0617-4
  7. Osipova VV, Filatova EG, Artemenko AR, et al. Brief recommendations of Russian experts on the diagnosis and treatment of migraine. RMZh. 2017;9:556-562. (In Russ.).
  8. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.  https://doi.org/10.1177/0333102417738202
  9. Robbins MS. Diagnosis and Management of Headache: A Review. JAMA. 2021;325(18):1874-1885. https://doi.org/10.1001/jama.2021.1640
  10. Reshetko OV, Grishin AI. Innovative drugs for the treatment of primary headaches: migraine. Kachestvennaya klinicheskaya praktika. 2019;2:95-104. (In Russ.). https://doi.org/10.24411/2588-0519-2019-10077
  11. Starodubtsev AI, Starodubtsev AA, Karpov SM, Vyshlova IA. Relief of pain in migraine. Russian Journal of Pain. 2017;1(52):95-96. (In Russ.).
  12. Azimova YE, Amelin AV, Alferova VV, Artemenko AR, Akhmadeeva LR, Golovacheva VA, Danilov AB, Ekusheva EV, Isagulyan ED, Koreshkina MI, Kurushina OV, Latysheva NV, Lebedeva ER, Naprienko MV, Osipova VV, Pavlov NA, Parfenov VA, Rachin AP, Sergeev AV, Skorobogatykh KV, Tabeeva GR, Filatova EG. Clinical guidelines «Migraine». S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1-3):4-36. (In Russ.). https://doi.org/10.17116/jnevro20221220134
  13. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008;48(8):1157-1168. https://doi.org/10.1111/j.1526-4610.2008.0121x
  14. Meshcherina MI. Clinical and pathophysiological characteristics of headaches caused by excessive drug intake: Dis. ... d-ra med. nauk. 2013;150. (In Russ.).
  15. Caronna E, Starling AJ. Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine. Neurol Clin. 2021;39(1):1-19.  https://doi.org/10.1016/j.ncl.2020.09.001
  16. Edvinsson L. CGRP and migraine: from bench to bedside. Rev Neurol (Paris). 2021;177(7):785-790.  https://doi.org/10.1016/j.neurol.2021.06.003
  17. Iyengar S, Ossipov MH, Johnson KW. The role of CGRP in peripheral and central pain mechanisms including migraine. Pain. 2016;158:543-559.  https://doi.org/10.1097/j.pain.0000000000000831
  18. Jain S, Yuan H, Spare N, Silberstein SD. Erenumab in the treatment of migraine. Pain Manag. 2018;8(6):415-426.  https://doi.org/10.2217/pmt-2018-0037
  19. Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther. 2019;19(12):1307-1317. https://doi.org/10.1080/14712598.2019.1671350
  20. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123-2132. https://doi.org/10.1056/NEJMoa1705848
  21. Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018;58(S1):4-16.  https://doi.org/10.1111/head.13300
  22. Hirata K, Takeshima T, Sakai F, et al. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies. Brain Behav. 2022;12(3):25-26.  https://doi.org/10.1002/brb3.2526
  23. Dobrynina LA, Gubanova MV, Belopasova AV, Baidina EV, Afanasev MA. The efficacy and safety of erenumab in patients with frequent episodic migraine according to the Russian real clinical practice study of the Scientific Center of Neurology. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(2):74-80. (In Russ). https://doi.org/10.17116/jnevro202212202174
  24. Belskaya GN, Kiryanova EA, Krasnikov AV, Prokopovich ME, Sakharova EV. Efficiency of erenumab in neurologist’s real practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7):74-80. (In Russ.). https://doi.org/10.17116/jnevro202212207174
  25. Ankrom W, Bondiskey P, Li CC, et al. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. Clin Transl Sci. 2020;13(3):462-472.  https://doi.org/10.1111/cts.12728
  26. Smith B, Rowe J, Watkins PB, et al. Mechanistic Investigations Support Liver Safety of Ubrogepant. Toxicol Sci. 2020;177(1):84-93.  https://doi.org/10.1093/toxsci/kfaa093
  27. Ornello R, Casalena A, Frattale I, et al. Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain. 2020;21(1):102-109.  https://doi.org/10.1186/s10194-020-01171-w
  28. Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine — a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108-118.  https://doi.org/10.1177/03331024211053571
  29. Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J. CGRP monoclonal antibodies in migraine: An efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22(1):128.  https://doi.org/10.1186/s10194-021-01335-2
  30. Ashina M, Goadsby PJ, Dodick DW, et al. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. JAMA Neurol. 2022;79(2):159-168.  https://doi.org/10.1001/jamaneurol.2021.4678
  31. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026-1037. https://doi.org/10.1177/0333102418759786
  32. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280-2287. https://doi.org/10.1016/S0140-6736(18)32534-0
  33. Schoenen J, Manise M, Nonis R, Gérard P, Timmermans G. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. Rev Neurol (Paris). 2020;176(10):788-803.  https://doi.org/10.1016/j.neurol.2020.04.027
  34. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-434.  https://doi.org/10.1016/S1474-4422(17)30083-2
  35. Ornello R, Baraldi C, Guerzoni S, et al. Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men. Front Neurol. 2021;12:774341. https://doi.org/10.3389/fneur.2021.774341
  36. Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis [published correction appears in Cephalalgia. 2022;42(1):90]. Cephalalgia. 2021;41(7):851-864.  https://doi.org/10.1177/0333102421989601
  37. Fang J, Korrer S, Johnson JC, et al. Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis. Adv Ther. 2021;38(6):2921-2934. https://doi.org/10.1007/s12325-021-01677-y
  38. Shibata M. Application of CGRP-Related Monoclonal Antibodies in Migraine Management. Brain Nerve. 2021;73(4):327-337.  https://doi.org/10.11477/mf.1416201763
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.